Literature DB >> 10524697

Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format.

T Pincus1, C Swearingen, F Wolfe.   

Abstract

OBJECTIVE: To develop components of a multidimensional Health Assessment Questionnaire (MDHAQ) through the addition of new items in the "patient-friendly" HAQ format, including advanced activities of daily living (ADL), designed to overcome "floor effects" of the HAQ and modified HAQ (MHAQ) in which patients may report normal scores although they experience meaningful functional limitations, and psychological items, designed to screen efficiently for psychological distress in routine care.
METHODS: The new MDHAQ items, as well as scales for pain, fatigue, helplessness, and global health status on a 2-page questionnaire, were completed by 688 consecutive patients with various rheumatic diseases, including 162 with rheumatoid arthritis (RA), 114 with fibromyalgia, 63 with osteoarthritis, 34 with systemic lupus erythematosus, 20 with vasculitis, 18 with psoriatic arthritis, 16 with scleroderma, and 261 with various other rheumatic diseases, over 2 years at a weekly academic rheumatology clinic.
RESULTS: The new MDHAQ items have good test-retest reliability and face validity. MHAQ scores were highest in patients with RA, and scores for other scales were highest in patients with fibromyalgia. On the advanced ADL, 58% of patients reported difficulty with errands, 68% with climbing stairs, 79% with walking two miles, 87% with participating in sports and games, and 94% with running or jogging two miles. On the psychological items, 75% of patients reported difficulty with sleep, 63% with stress, 61% with anxiety, and 57% with depression. Normal MHAQ scores were reported by 23% of patients and normal HAQ scores by 16% of patients who completed these questionnaires, while fewer than 5% had normal scores on the MDHAQ.
CONCLUSION: The MDHAQ items overcome in large part the "floor effects" seen on the HAQ and MHAQ, and are useful to screen for problems with sleep, stress, anxiety, and depression in the "patient-friendly" HAQ format. These data support the value of completion of a simple 2-page patient questionnaire by each patient at each visit to a rheumatologist.

Entities:  

Mesh:

Year:  1999        PMID: 10524697     DOI: 10.1002/1529-0131(199910)42:10<2220::AID-ANR26>3.0.CO;2-5

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  104 in total

1.  Anti-CCP antibody in patients with established rheumatoid arthritis: Does it predict adverse cardiovascular profile?

Authors:  Banerjee Arnab; Ghosh Biswadip; Pande Arindam; Mandal Shyamash; Ghosh Anirban; Palui Rajan
Journal:  J Cardiovasc Dis Res       Date:  2013-06-18

2.  Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study.

Authors:  Iván Ferraz-Amaro; Daniel Seoane-Mato; Fernando Sánchez-Alonso; María A Martín-Martínez
Journal:  Rheumatol Int       Date:  2015-09-24       Impact factor: 2.631

3.  Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis.

Authors:  P P Katz; A Morris; E H Yelin
Journal:  Ann Rheum Dis       Date:  2005-10-25       Impact factor: 19.103

4.  Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?

Authors:  Nasim Ahmed Khan; Horace Jack Spencer; Essam Ahmed Abda; Rieke Alten; Christof Pohl; Codrina Ancuta; Massimiliano Cazzato; Pál Géher; Laure Gossec; Dan Henrohn; Merete Lund Hetland; Nevsun Inanc; Johannes Wg Jacobs; Eduardo Kerzberg; Maria Majdan; Omondi Oyoo; Ruben A Peredo-Wende; Zahraa Ibrahim Selim; Fotini Nikolaos Skopouli; Alberto Sulli; Kim Hørslev-Petersen; Peter C Taylor; Tuulikki Sokka
Journal:  Ann Rheum Dis       Date:  2012-04-24       Impact factor: 19.103

5.  Multidimensionality of the PROMIS self-efficacy measure for managing chronic conditions.

Authors:  Mi Jung Lee; Sergio Romero; Craig A Velozo; Ann L Gruber-Baldini; Lisa M Shulman
Journal:  Qual Life Res       Date:  2019-02-26       Impact factor: 4.147

6.  Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease.

Authors:  Jeffrey J Swigris; Janelle Yorke; David B Sprunger; Christopher Swearingen; Theodore Pincus; Roland M du Bois; Kevin K Brown; Aryeh Fischer
Journal:  Respir Med       Date:  2010-05-14       Impact factor: 3.415

7.  Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis.

Authors:  Jeremy Sokolove; Dannette S Johnson; Lauren J Lahey; Catriona A Wagner; Danye Cheng; Geoffrey M Thiele; Kaleb Michaud; Harlan Sayles; Andreas M Reimold; Liron Caplan; Grant W Cannon; Gail Kerr; Ted R Mikuls; William H Robinson
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

8.  Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis.

Authors:  T Pincus; G Koch; H Lei; B Mangal; T Sokka; R Moskowitz; F Wolfe; A Gibofsky; L Simon; S Zlotnick; J G Fort
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

9.  Patient reported outcomes and analgesia use in osteoarthritis of the knee.

Authors:  S Mody; M Jolly; M J Kwasny; J A Block
Journal:  Osteoarthritis Cartilage       Date:  2008-05-05       Impact factor: 6.576

10.  A biomarker of n-3 compliance in patients taking fish oil for rheumatoid arthritis.

Authors:  Leslie G Cleland; Susanna M Proudman; Cindy Hall; Lisa K Stamp; Leah McWilliams; Nicole Wylie; Mark Neumann; Robert A Gibson; Michael J James
Journal:  Lipids       Date:  2003-04       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.